Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-5902 at AACR 102nd Annual Meeting Mar 30, 2011
Rexahn Pharmaceuticals Enrolls 100 Patients in Serdaxin(R) Phase IIb Clinical Trial for Depression Mar 23, 2011
Rexahn Pharmaceuticals to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference Mar 14, 2011
Rexahn Pharmaceuticals Granted European Patent for New Quinoxalinyl-piperazine Compounds Feb 28, 2011
Teva Pharmaceutical Increases Its Investment in Rexahn for the Continued Research and Development of the Pre-Clinical Anti-Cancer Compound, RX-3117 Jan 20, 2011
Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data at the American College of Neuropsychopharmacologists Annual Meeting Dec 8, 2010